JP2013531051A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013531051A5 JP2013531051A5 JP2013520108A JP2013520108A JP2013531051A5 JP 2013531051 A5 JP2013531051 A5 JP 2013531051A5 JP 2013520108 A JP2013520108 A JP 2013520108A JP 2013520108 A JP2013520108 A JP 2013520108A JP 2013531051 A5 JP2013531051 A5 JP 2013531051A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylene
- 5alkyl
- compound
- fluoroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 82
- 125000002947 alkylene group Chemical group 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 claims 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000003945 NF-kappa B Human genes 0.000 claims 1
- 108010057466 NF-kappa B Proteins 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 claims 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000011987 methylation Effects 0.000 claims 1
- 238000007069 methylation reaction Methods 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000035790 physiological processes and functions Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000003419 tautomerization reaction Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1050815-8 | 2010-07-19 | ||
| SE1050815 | 2010-07-19 | ||
| PCT/EP2011/062243 WO2012010555A1 (en) | 2010-07-19 | 2011-07-18 | Tricyclic lactones for treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013531051A JP2013531051A (ja) | 2013-08-01 |
| JP2013531051A5 true JP2013531051A5 (enExample) | 2014-09-04 |
| JP5855098B2 JP5855098B2 (ja) | 2016-02-09 |
Family
ID=44514663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013520108A Expired - Fee Related JP5855098B2 (ja) | 2010-07-19 | 2011-07-18 | 癌の処置のための三環式ラクトン類 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9150531B2 (enExample) |
| EP (1) | EP2595972B1 (enExample) |
| JP (1) | JP5855098B2 (enExample) |
| CN (1) | CN103097368B (enExample) |
| ES (1) | ES2553248T3 (enExample) |
| WO (1) | WO2012010555A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2925728A4 (en) * | 2012-11-27 | 2016-11-02 | Glaxosmithkline Llc | COMBINATION |
| EP3114114B1 (en) * | 2014-03-07 | 2018-10-10 | Glactone Pharma Development AB | Tricyclic prodrugs |
| JP2016193870A (ja) * | 2015-04-01 | 2016-11-17 | 国立大学法人広島大学 | 慢性骨髄性白血病治療剤 |
| SE539204C2 (en) | 2015-06-05 | 2017-05-09 | Glactone Pharma Dev Ab | Ether analogues of galiellalactone |
| SE540295C2 (en) | 2016-12-05 | 2018-05-29 | Glactone Pharma Dev Ab | Sulfonamide analogues of galiellalactone |
| CN111297898B (zh) * | 2020-02-18 | 2022-01-25 | 山东大学齐鲁医院 | 间充质干细胞来源的细胞外囊泡在脑缺血再灌注损伤中的应用 |
| CN114507203B (zh) * | 2020-11-17 | 2025-09-30 | 华东理工大学 | 具有抗炎和抗癌活性的倍半萜内酯衍生物及其制备方法和用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002002109A1 (de) | 2000-07-03 | 2002-01-10 | Institut Für Biotechnologie Und Wirkstoff-Forschung E.V. | Verwendung von galiella-lacton |
| WO2008135419A2 (en) | 2007-05-04 | 2008-11-13 | Charité Universitätsmedizin Berlin | Anti-il-6-agents for improving primary functioning of allogenic grafts |
-
2011
- 2011-07-18 CN CN201180035500.3A patent/CN103097368B/zh not_active Expired - Fee Related
- 2011-07-18 WO PCT/EP2011/062243 patent/WO2012010555A1/en not_active Ceased
- 2011-07-18 JP JP2013520108A patent/JP5855098B2/ja not_active Expired - Fee Related
- 2011-07-18 EP EP11739028.6A patent/EP2595972B1/en not_active Not-in-force
- 2011-07-18 ES ES11739028.6T patent/ES2553248T3/es active Active
- 2011-07-18 US US13/811,015 patent/US9150531B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013531051A5 (enExample) | ||
| ES2925564T3 (es) | Derivados de azetidina tal como moduladores de receptores de quimiocinas y usos de los mismos | |
| JP2009504763A5 (enExample) | ||
| RU2014131014A (ru) | Димерные соединения-агонисты рецептора fgf (fgfr), способ их получения и их терапевтическое применение | |
| NZ598085A (en) | Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid | |
| JP2019517487A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| JP2010514829A5 (enExample) | ||
| CN107921031A (zh) | 给予谷氨酰胺酶抑制剂的方法 | |
| JP2007507494A5 (enExample) | ||
| IL205501A (en) | Preparation of preparations for the treatment of arthritis | |
| JP2011527333A5 (enExample) | ||
| JP2017518360A5 (enExample) | ||
| JP2014505107A5 (enExample) | ||
| KR20170081228A (ko) | 티족사나이드, 그의 유사체 또는 염의 전구 약물을 이용한 치료 조성물 및 방법 | |
| RU2017118165A (ru) | Ингибиторы энхансера гомолога 2 zestes | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| RU2009144538A (ru) | Новые циклические пептидные соединения | |
| RU2013141559A (ru) | Способ ингибирования клеток опухоли гамартомы | |
| JP2019535723A5 (enExample) | ||
| RU2015135722A (ru) | Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение | |
| RU2013148146A (ru) | Производные адамантила | |
| RU2012135698A (ru) | Способ и композиция | |
| JP2016525104A5 (enExample) | ||
| JP2018507257A5 (enExample) |